Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 11;12(1):e008148. doi: 10.1136/jitc-2023-008148

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Case illustration and treatment disposition of patient 7. (A) Timeline depicts time since first treatment administration. Dots indicate treatment administration as indicated on day 1 and day 2. Arrows indicate significant lesions. Syringe indicates injected lesion. Whole body 18F-FDG-PET/CT images are shown, together with a zoomed axial fusion image (PET/CT) of the lung lesion (non-injected). (B) Representative images from multiplex immunohistochemistry analysis at baseline (upper panel) and while on treatment (week 12, lower panel). Left images are overview full fluorescent scans before spectral deconvolution with indication (grid) of individual multispectral images (MSI) analyzed. Right images show selected MSI and analysis of immune cell composition of tumor region indicating a progressive decrease of detectable tumor region and influx of immune cells (mostly CD4 and CD8) while on treatment. IV, intravenous; IT, intratumoral; myDCs, myeloid dendritic cells; NGS, next generation sequencing results (mutated genes); PD, progressive disease; PR, partial response; SD, stable disease.